0IT.F · iCo Therapeutics Inc

-

Please sign in to comment on 0IT.F

1 Comment

Admin

3 years, 7 months ago

iCo Therapeutics Inc is currently in a long term uptrend where the price is trading 72.4% above its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

iCo Therapeutics Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 62.5% to $-193K since the same quarter in the previous year.

Finally, its free cash flow grew by 70.9% to $-193K since the same quarter in the previous year.

Based on the above factors, iCo Therapeutics Inc gets an overall score of 4/5.

Industry	Biotechnology
Sector	Healthcare
ISIN	None
CurrencyCode	EUR
Exchange	F

Target Price	None
Market Cap	12M
PE Ratio	None
Beta	2.73
Dividend Yield	None

ABOUT

iCo Therapeutics Inc

Satellos Bioscience Inc., a regenerative medicine company, develops therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program focuses on the development of a therapeutic for correcting the impaired muscle regenerative process in Duchenne muscular dystrophy (DMD), a genetic disease that involves the mutation and functional disruption of the DMD gene and loss of Dystrophin. The company was incorporated in 2012 and is headquartered in Toronto, Canada.

0IT.F · iCo Therapeutics Inc

-

iCo Therapeutics Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest iCo Therapeutics Inc using a moving average strategy